Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) Profit After Tax: 2016-2024

Historic Profit After Tax for Protagonist Therapeutics (PTGX) over the last 9 years, with Dec 2024 value amounting to $275.2 million.

  • Protagonist Therapeutics' Profit After Tax fell 18.46% to -$39.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.9 million, marking a year-over-year decrease of 73.13%. This contributed to the annual value of $275.2 million for FY2024, which is 448.54% up from last year.
  • As of FY2024, Protagonist Therapeutics' Profit After Tax stood at $275.2 million, which was up 448.54% from -$79.0 million recorded in FY2023.
  • In the past 5 years, Protagonist Therapeutics' Profit After Tax registered a high of $275.2 million during FY2024, and its lowest value of -$127.4 million during FY2022.
  • Its 3-year average for Profit After Tax is $22.9 million, with a median of -$79.0 million in 2023.
  • Its Profit After Tax has fluctuated over the past 5 years, first tumbled by 89.80% in 2021, then skyrocketed by 448.54% in 2024.
  • Yearly analysis of 5 years shows Protagonist Therapeutics' Profit After Tax stood at -$66.2 million in 2020, then slumped by 89.80% to -$125.6 million in 2021, then dropped by 1.47% to -$127.4 million in 2022, then soared by 38.02% to -$79.0 million in 2023, then skyrocketed by 448.54% to $275.2 million in 2024.